# A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older

> **NCT04908683** · PHASE3 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 25236 (actual)

## Conditions studied

- Respiratory Syncytial Viruses
- Lower Respiratory Tract Disease

## Interventions

- **BIOLOGICAL:** Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04908683
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-21
- **Primary completion:** 2023-07-21
- **Final completion:** 2023-07-21
- **Target enrollment:** 25236 (ACTUAL)
- **Last updated:** 2025-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04908683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04908683, "A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04908683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*